Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit
REHOVOT, Israel, Jan. 23, 2024 /PRNewswire/ -- Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), announced its CEO, Dr. Elran Haber, will participate in the 8th Annual Microbiome Movement Drug Development Summit Europe in Barcelona, Spain, from January 30 to February 1, 2024.
https://mma.prnewswire.com/media/1974949/Biomica.jpg
The summit gathers leading drug developers and microbiome experts to discuss microbiome functionality, translation, clinical development, biomarker discovery, and manufacturing scale-up. Dr. Haber will join two industry panel discussions: "The Future of Microbiome Therapeutics as Co-therapies: Investment & Development Considerations" on January 30, 2024, at 3:30pm GMT, and "Microbiome Business Pioneers: An Evaluation of Microbiome Industry Verticals & Future Perspectives" on February 1, 2024, at 4:15pm GMT.
Dr. Haber will be available for one-on-one meetings at the conference, and interested parties can contact the investor or public relations team.
About Biomica Ltd.:
Biomica is a clinical stage biopharmaceutical company developing innovative microbiome-based therapeutics utilizing PRISM system, a proprietary computational platform powered by Evogene's MicroBoost AI tech-engine. licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN).
For more information, please visit www.biomicamed.com
About Evogene Ltd.:
Evogene (Nasdaq: EVGN, TASE: EVGN) is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI - leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
Evogene uses its tech-engines to develop products through subsidiaries and strategic partnerships. Evogene's subsidiaries currently utilize the tech-engines to develop human microbiome-based therapeutics by Biomica, ag-biologicals by Lavie Bio, ag-chemicals by AgPlenus, medical cannabis products by Canonic and castor varieties, for the biofuel and other industries, by Casterra.
For more information, please visit: www.evogene.com
Contacts
Rachel Pomerantz Gerber
Head of Investor Relations at Evogene
rachel.pomerantz@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/1974949/Biomica.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original content:https://www.prnewswire.com/news-releases/biomica-ceo-set-to-engage-in-panel-discussion-at-8th-annual-european-microbiome-movement-summit-302041863.html
SOURCE Biomica Ltd.
